Skip to content
Screener
Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
-$131.01M+23.8%-$117.5M+42.0%-$108.12M+39.6%-$162.25M-69.3%-$171.9M-76.2%
$18.17M-23.8%$19.67M+1.8%$19.48M+50.4%$21.04M+192%$23.85M+166%
$19.5M-25.5%$22.22M-38.4%$23.76M-22.8%$25.24M+38.3%$26.16M+58.3%
-$105.95M-38.6%-$81.1M+38.5%-$46.07M+60.1%-$117.36M-98.2%-$76.42M+7.1%
$44K-98.6%$258K-85.9%$1.24M-4.2%$243K-94.7%$3.15M+166%
-$1.96M+66.3%-$338K+95.4%-$1.24M-100%-$2.55M+44.1%-$5.81M-38.9%
$2.25M+8.0%$2.21M+7.9%$2.17M+3.1%$2.13M-7.0%$2.08M+7,915%
-$1.27M-101%-$3.47M-109%$132.01M+1,141%$251.34M+1,427%$97.66M-62.9%
-$108.36M-539%-$88.74M+5.5%$86.78M-48.1%$133.3M$24.69M-86.0%
-$105.99M-33.2%-$81.36M+39.2%-$47.32M+59.5%-$117.6M-84.4%-$79.57M+4.6%

FAQ

How much cash does Recursion Pharmaceuticals, Inc. generate?
Recursion Pharmaceuticals, Inc. (RXRX) generated -$350.5M in operating cash flow over the trailing twelve months.
What is Recursion Pharmaceuticals, Inc.'s free cash flow?
After $1.8M of capital expenditures, Recursion Pharmaceuticals, Inc.'s free cash flow was -$352.3M over the trailing twelve months, up 10.6% year over year.
Where does Recursion Pharmaceuticals, Inc.'s cash flow data come from?
Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.